September 29th 2025
While the MFN executive order targets drug companies for drug prices, Peter Rubin discusses how health plans also play a large role in this area.
September 26th 2025
September 17th 2025
Advancing Innovation in Cancer Care: Bringing the Next Wave of Oncology Products to Market
July 8th 2025While the growing oncology pipeline offers tremendous potential, the path from clinical development through to commercial launch and patient administration is complex and lined with challenges that can impact product success and access.
Orders of Magnitude: Gauging Future Pricing-and-Policy Reverberations in Pharma
June 27th 2025Q&A with Model N's Michael Grosberg drills deeper into the new US drug pricing directives, including challenges in implementation, the potential unintended consequences, and how these actions could spark the shift to outcomes-based contracting in healthcare.